• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    11/14/24 3:32:10 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email
    SC 13G/A 1 form_sc13ga-standard.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
     
    Standard BioTools Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
     (Title of Class of Securities)

    34385P108
    (CUSIP Number)
     
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     
     
     
     
    ☒
    Rule 13d-1(b)
     
    ☐
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     



    CUSIP No. 34385P108
     
    SCHEDULE 13G
           
     
    1
    NAME OF REPORTING PERSONS.
     
    Indaba Capital Management, L.P.
     
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [   ]
    (b) [X]
     
     3
    SEC Use Only
      
     
    4
    Citizenship or Place of Organization
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
     
     
     
    5
     
    Sole Voting Power
     
    0
     
     
     
    6
     
     
    Shared Voting Power
     
    2,641,379 (1)
     
     
     
    7
     
    Sole Dispositive Power
     
    0
     
     
     
    8
     
    Shared Dispositive Power
     
    2,641,379 (1)
     
     
     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,641,379 (1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [   ]
      
     
    11
     
    Percent of Class Represented by Amount in Row (9)
     
    0.7% (1)(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IA, PN
     

    (1) Amount reported includes 2,641,379 shares of common stock of Standard BioTools Inc. (the “Issuer”) issuable upon conversion of the Issuer’s 5.25% Convertible Senior Notes due 2024 (the “Notes”). 

    (2) Based on 371,154,471 shares of the Issuer’s common stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 6, 2024.

    CUSIP No. 34385P108
     
    SCHEDULE 13G
           
     
    1
    NAME OF REPORTING PERSONS.
     
    IC GP, LLC
     
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [   ]
    (b) [X]
     
     3
    SEC Use Only
      
     
    4
    Citizenship or Place of Organization
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
     
     
     
    5
     
    Sole Voting Power
     
    0
     
     
     
    6
     
     
    Shared Voting Power
     
    2,641,379 (1)
     
     
     
    7
     
    Sole Dispositive Power
     
    0
     
     
     
    8
     
    Shared Dispositive Power
     
    2,641,379 (1)
     
     
     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,641,379 (1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [   ]
      
     
    11
     
    Percent of Class Represented by Amount in Row (9)
     
    0.7% (1)(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    OO, HC
     

    (1) Amount reported includes 2,641,379 shares of the Issuer’s common stock issuable upon conversion of the Notes. 

    (2) Based on 371,154,471 shares of the Issuer’s common stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.



    CUSIP No. 34385P108
     
    SCHEDULE 13G
           
     
    1
    NAME OF REPORTING PERSONS.
     
    Derek C. Schrier
     
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [   ]
    (b) [X]
     
     3
    SEC Use Only
      
     
    4
    Citizenship or Place of Organization
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
     
     
     
    5
     
    Sole Voting Power
     
    0
     
     
     
    6
     
     
    Shared Voting Power
     
    2,641,379 (1)
     
     
     
    7
     
    Sole Dispositive Power
     
    0
     
     
     
    8
     
    Shared Dispositive Power
     
    2,641,379 (1)
     
     
     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,641,379 (1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [   ]
      
     
    11
     
    Percent of Class Represented by Amount in Row (9)
     
    0.7% (1)(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IN, HC
     

    (1) Amount reported includes 2,641,379 shares of the Issuer’s common stock issuable upon conversion of the Notes.

    (2) Based on 371,154,471 shares of the Issuer’s common stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.


    Amendment No. 5 to Schedule 13G

     Item 1.
     
     
     
     
     
     
     
     
     
     
     
    (a)
    Name of Issuer
     
     
     
     
    Standard BioTools Inc. (the “Issuer”)
     
     
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
     
    2 Tower Place, Suite 2000, South San Francisco, CA 94080
     
    Item 2.
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    (a)
    Name of Person Filing
     
     
     
     
    This Schedule 13G is being filed jointly on behalf of:
     
    (i) Indaba Capital Management, L.P., a Delaware limited partnership (the "Investment Manager"),
     
    (ii) IC GP, LLC, a Delaware limited liability company, and the Investment Manager’s sole general partner (“IC GP”), and
     
    (iii) Derek C. Schrier, a United States citizen and the Managing Member of IC GP (the “Managing Member” and, collectively with the Investment Manager and IC GP, the “Reporting Persons”).
     
     
     
    (b)
    Address of Principal Business office or, if None, Residence
     
     
     
    The business address of each of the Reporting Persons is One Letterman Drive, Building D, Suite DM700, San Francisco, California 94129.
     
     
     
    (c)
    Citizenship:
     
     
     
     
    The Investment Manager is a Delaware limited partnership, IC GP is a Delaware limited liability company and the Managing Member is a United States citizen.
     
     
     
    (d)
    Title of Class Securities:
     
     
     
     
    Common Stock, par value $0.001 per share (“Common Stock”)
     
     
     
    (e)
    CUSIP Number:
     
     
     
     
    34385P108
     
     
     

     
     
    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     
     
     
    (a) [  ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
     
     
     
    (b) [  ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
     
     
    (c) [  ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
     
     
    (d) [  ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
     
     
     
    (e) [X] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
     
     
     
    (f)  [  ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
     
     
     
    (g) [X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
     
     
     
    (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
     
     
    (i)  [  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
     
     
    (j)  [  ] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
     
     
     
    (k) [  ] Group, in accordance with 240.13d-1(b)(1)(ii)(K).
     

    Item 4.
    Ownership
     
    (a) Amount beneficially owned:
     
    As of September 30, 2024, the Reporting Persons beneficially owned the shares of Common Stock referenced in Item 9 of the cover page pertaining to each Reporting Person and such Item 9 disclosure is incorporated herein by reference.

    The shares of Common Stock beneficially owned by the Reporting Persons are directly held by Indaba Capital Fund, L.P. (the “Fund”), a private investment fund for which the Investment Manager serves as investment manager.  Pursuant to an Investment Management Agreement, the Fund and its general partner have delegated all voting and investment power over the shares of Common Stock directly held by the Fund to the Investment Manager.
      
    (b) Percent of class:
     
    Incorporated by reference to Item 11 of the cover page pertaining to each Reporting Person.

    (c) Number of shares to which the person has:
     
     
    (i) Sole power to vote or to direct the vote:
     
     
    Incorporated by reference to Item 5 of the cover page pertaining to each Reporting Person.
     
     
    (ii) Shared power to direct the vote:
     
     
    Incorporated by reference to Item 6 of the cover page pertaining to each Reporting Person.
     
     
    (iii) Sole power to dispose or to direct the disposition of:
     
     
    Incorporated by reference to Item 7 of the cover page pertaining to each Reporting Person.
     
     
    (iv) Shared power to dispose or to direct the disposition of:
     
     
    Incorporated by reference to Item 8 of the cover page pertaining to each Reporting Person.
     
     

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following [X].
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.   
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
     
    Item 9.
     
    Notice of Dissolution of Group.

    Not applicable.
     
    Item 10.
      Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  November 14, 2024
     
     
    INDABA CAPITAL MANAGEMENT, L.P.
     
     
     
     
     
    By:
     IC GP, LLC, its general partner
     
     
     
     
     
     
    By:
     /s/ Derek C. Schrier
     
     
     
    Name: Derek C. Schrier
     
     
     
    Title: Managing Member
     
     
     
     
     
     
    IC GP, LLC
     
     
     
     
     
     
    By:
     /s/ Derek C. Schrier
     
     
     
    Name: Derek C. Schrier
     
     
     
    Title: Managing Member
     
     
     
     
     
     
     
     
     
     
    /s/ Derek C. Schrier 
     
     
    DEREK C. SCHRIER 
     
      
     
    Get the next $LAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    8/13/2025$1.55Buy → Hold
    TD Cowen
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    SEC Filings

    View All

    SEC Form S-8 filed by Standard BioTools Inc.

    S-8 - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    8/15/25 4:11:45 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Standard BioTools Inc.

    10-Q - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    8/15/25 4:05:59 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form NT 10-Q filed by Standard BioTools Inc.

    NT 10-Q - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    8/11/25 8:19:25 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/15/25 9:18:22 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    3/4/25 8:19:51 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/29/24 8:30:41 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Standard BioTools downgraded by TD Cowen with a new price target

    TD Cowen downgraded Standard BioTools from Buy to Hold and set a new price target of $1.55

    8/13/25 8:03:50 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

    2/27/25 6:22:46 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    TD Cowen initiated coverage on Standard BioTools with a new price target

    TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

    4/16/24 8:09:43 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/15/25 9:18:22 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Kim Hanjoon Alex was granted 1,500,000 shares, increasing direct ownership by 159% to 2,440,564 units (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/5/25 6:33:03 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Egholm Michael was granted 3,000,000 shares, increasing direct ownership by 110% to 5,736,285 units (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    8/5/25 6:23:22 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

    PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K biobank following a comprehensive evaluation of competitive proteomics offerings. The combination of unmatched proteome coverage, superior reproducibility and high-quality service offering

    8/6/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Financials

    Live finance-specific insights

    View All

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Reports First Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

    5/6/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    View All

    Standard BioTools Appoints Alex Kim as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

    11/7/24 8:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

    5/15/23 7:30:14 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/14/24 3:32:10 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/12/24 6:01:47 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/4/24 1:59:57 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials